Idia AS has successfully completed the first clinical trial with its proprietary kiwifruit extract.

March 5, 2015

Idia AS has succesfully completed the first clinical trial with its proprietary kiwifruit extract.  The headline results from this randomized, double-blinded and placebo-controlled cross-over study in 50 subjects gives evidence of a clinically relevant reduction in systolic blood pressure in the target population. 

 

The extract will now enter into the next step of the clinical development program. 

 

For further information, please contact the CEO at Idia, Ole Peter Nordby at op@idia.no.

 

 

Please reload

Featured Posts

Idia AS has succesfully completed the first clinical trial with its proprietary kiwifruit extract.  The headline results from this randomized, double-...

Idia AS has successfully completed the first clinical trial with its proprietary kiwifruit extract.

March 5, 2015

1/1
Please reload

Recent Posts
Please reload

Archive
Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square

© 2015 by Idia AS.

 

  • LinkedIn Black Square
  • Twitter Black Square